Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
recombinant adenovirus-p53 SCH-58500 · 1 trial · 4 indications
| Name | Type | Description |
|---|---|---|
| recombinant adenovirus-p53 SCH-58500 | BIOLOGICAL | - |
DISEASE CHARACTERISTICS: Radiographic or surgical evidence of primary ovarian, fallopian tube, or peritoneal carcinoma Ascites cytologically positive for peritoneal carcinomatosis from recurrent or persistent ovarian, fallopian tube, or peritoneal carcinoma Must have ascites and tumor accessible by ...
Recombinant adenovirus-p53 SCH-58500 is an investigational gene therapy that was studied in patients with primary ovarian, fallopian tube, or peritoneal cancer. It was tested in a Phase 1 trial that enrolled 59 women with these cancers, including metastatic disease. The trial has been completed.
Recombinant adenovirus-p53 SCH-58500 targets the p53 tumor suppressor protein, which is encoded by the TP53 gene. The agent is designed to deliver a functional copy of p53 into tumor cells. Its target class is an exogenous protein, meaning the therapeutic effect comes from introducing an external protein rather than modulating an endogenous target.
Recombinant adenovirus-p53 SCH-58500 is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company sponsored the Phase 1 clinical trial of the agent in patients with ovarian, fallopian tube, or peritoneal cancer.
Recombinant adenovirus-p53 SCH-58500 is in Phase 1 clinical development. It is an investigational therapy and has not been approved by the FDA. The single Phase 1 trial of this agent has been completed, and no active trials are currently listed.
Recombinant adenovirus-p53 SCH-58500 was evaluated in one completed Phase 1 clinical trial, NCT00002960, titled SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084). The trial enrolled 59 female patients aged 18 years and older and was an uncontrolled, non-randomized study.